, Tracking Stock Market Picks
Enter Symbol:
Oncolytics Biotech, Inc. (ONCY) [hlAlert]

down 92.20 %

Oncolytics Biotech, Inc. (ONCY) rated Outperform with price target $5 by RBC Capital Mkts

Posted on: Thursday,  Sep 13, 2012  1:25 PM ET by RBC Capital Mkts

RBC Capital Mkts rated Outperform Oncolytics Biotech, Inc. (NASDAQ: ONCY) on 09/13/2012. Previously RBC Capital Mkts rated Outperform Oncolytics Biotech, Inc. (NASDAQ: ONCY)
on 12/22/2010., when the stock price was $6.80. Since then, Oncolytics Biotech, Inc. has lost 92.21% as of 11/04/2015's recent price of $0.53.
If you would have followed the previous RBC Capital Mkts's recommendation on ONCY, you would have lost 92.2% of your investment in 1778 days.

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.

RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/13/2012 1:25 PM Buy
2.61 5.00
as of 12/31/2012
1 Week up  9.80 %
1 Month up  64.01 %
3 Months up  68.24 %
1 YTD up  0.51 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2010 9:25 AM Buy
6.80 7.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy